Taiga Biotechnologies, Inc.'s technology is centered around boosting the immune system to better fight disease.
BRAND NEW CLASS OF CELL THERAPY
TBX-4000 = TAT PROTEIN + MYC PROTEIN
-
TBX-4000 is a proprietary protein of Taiga Biotechnologies, Inc. and is a fusion of the Trans-Activator Transcription (TAT) protein and the MYC protein. TBX-4000 is crucial to the development and function of TBX-3400 and TBX-2400.
TURNING UP THE IMMUNE SYSTEM
-
MYC is the key regulator of cellular function.
-
TAT is the “payload” carrier that enables TBX-4000 to penetrate the cell membrane.
-
Once inside the cell, MYC is shuttled to the nucleus where it exerts its function.

Reviewed By US FDA, EMA, Japan MHLW, Israel MoH

TBX-4000 master file with the FDA
![Our-Key-Diference_PPT_Taiga_vFOL[14].png](https://static.wixstatic.com/media/ae3e2a_38c505d50393418aa7aa3864c74590ed~mv2.png/v1/crop/x_0,y_257,w_2376,h_1345/fill/w_712,h_404,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Our-Key-Diference_PPT_Taiga_vFOL%5B14%5D.png)
MULTIPLE APPLICATIONS
![Technology-Platform_PPT_Taiga_vFOL[44].png](https://static.wixstatic.com/media/ae3e2a_e264f79f8b874b6f99bb1dec5b8635a1~mv2.png/v1/crop/x_0,y_439,w_2376,h_1397/fill/w_671,h_395,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Technology-Platform_PPT_Taiga_vFOL%5B44%5D.png)
HOW IT WORKS COMPARED TO OTHER THERAPIES
T-Cell Activation
Activation of the T-cell
T-cells identify tumor cells and become activated through a series of interactions.
When activated, the T-cell:
-
Targets and kills the tumor cell.
-
Proliferates, creating more T-cells that are able to identify and kill the tumor cell.
Tumor Evading Attack
Evade attack from the T-cell
Tumors evade T-cell attack by disguising themselves as “self” cells through the use of immune checkpoint receptors on its cell surface.
Two Mechanisms:
-
Certain Immune Checkpoints compete for the Signal 2 binding site on the Tumor Cell, inhibiting Signal 2 from occurring.
-
Other Immune Checkpoints interactions occur which lead to further inactivation of the T-Cell.
Checkpoint Inhibitors
Blocking the Immune Checkpoint Receptor
Competitors have developed therapies that use one or a combination of checkpoint inhibitors to block the interaction.
Issues:
-
Can become Relapsed or Refractory to the treatment.
-
Severe Toxicities, Autoimmune complications.
TBX-3400
Down-regulate the Checkpoint Receptors
We have data that shows TBX-3400 cells show decreased expression of immune checkpoint receptors.
Without these checkpoint receptors expressed, the T-cell is able to become activated, recognize the tumor and kill it.
Advantages:
-
Simple approach, down-regulates checkpoints.
-
Agnostic to solid tumor type.
-
Autologous, well-tolerated.



